NCT06881173 The Effectiveness of Bu Zhong Yi Qi Tang in Patients with Myasthenia Gravis
| NCT ID | NCT06881173 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cheng, yu-ting |
| Condition | Myasthenia Gravis |
| Study Type | INTERVENTIONAL |
| Enrollment | 112 participants |
| Start Date | 2022-06-14 |
| Primary Completion | 2025-06-13 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 112 participants in total. It began in 2022-06-14 with a primary completion date of 2025-06-13.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Research Background: According to the Myasthenia Gravis Foundation of America (MGFA, 2015), the estimated prevalence of myasthenia gravis is 14-20 per 100,000 people, with a higher prevalence in young female individuals compared to males. However, as individuals age, especially after the age of 50, the prevalence in males becomes higher than in females. myasthenia gravis patients often experience varying degrees of disability, leading to the need for long-term medical care, medication, and lifestyle adjustments. This also gives rise to subsequent challenges in caregiving, affecting both the patients' families and society.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with ocular myasthenia by a doctor * Western medicine prescriptions only take oral Mestinon (Pyrido stigmine Bromide) * Patients over 20 years old * Can understand and understand Those who can speak Mandarin or Taiwanese * those with a clear state of consciousness and no diagnosis of mental illness * patients and their families who are willing to receive precise integrated treatment of traditional Chinese and Western medicine. Exclusion Criteria: * Patients with liver failure or kidney failure * Allergy symptoms to traditional Chinese medicine, such as skin itching and redness * Patients with malignant tumors * Patients currently undergoing radiotherapy and chemotherapy * Pregnant * Cardiac rhythm device implementer
Contact & Investigator
Ju-Han Liu
STUDY CHAIR
project leader
Frequently Asked Questions
Who can join the NCT06881173 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Myasthenia Gravis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06881173 currently recruiting?
Yes, NCT06881173 is actively recruiting participants. Contact the research team at tyghaw3261635@gmail.com for enrollment information.
Where is the NCT06881173 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06881173 clinical trial?
NCT06881173 is sponsored by Cheng, yu-ting. The principal investigator is Ju-Han Liu at project leader. The trial plans to enroll 112 participants.